JPRN-UMIN000010769已完成未知
Glargine plus Lixisenatide or vildagliptin succeeding to BOT T2DM control evaluation trial in Kobe - GLP-ONE KOBE study
Kobe University Graduate school of medicine diabetes and endocrinology0 个研究点目标入组 48 人开始时间: 2013年6月15日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 48
研究概览
简要总结
HbA1c decreased equally, lixisenatide had the larger BW reduction effect than vildagliptin
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 90years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Renal or Liver dysfunction Pregnant or breast-feeding women Slowly progressive T1DM
研究者
相似试验
进行中（未招募）
1 期
Effect of insulin glargine and lixisenatide versus insulin glargine on brain insulin sensitivity in patients with type 2 diabetesEUCTR2018-003557-21-DEniversity Hospital Tuebingen40
已完成
3 期
Efficacy and Safety of LixiLan Versus Insulin Glargine Alone Both With Metformin in Japanese With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic DrugsType 2 Diabetes MellitusNCT02752412Sanofi513
已完成
3 期
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Insulin Glargine Alone on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in JapanType 2 Diabetes MellitusNCT02752828Sanofi521
已完成
3 期
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Lixisenatide on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in JapanType 2 Diabetes MellitusNCT02749890Sanofi321
招募中
不适用
Effect of insulin glargine and lixisenatide and insulin degludec and liraglutide on glucose variability and oxidative stress in type 2 diabetes patientsType 2 diabetes mellitusJPRN-UMIN000043068Showa University School of Medicine, Division of Diabetes and Endocrinology, Department of Internal Medicine30